4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer differing levels of exposure to the prostate-cancer market, spanning established therapies and development-stage programs. The investment cases are driven by a mix of existing drug sales, clinical-trial milestones and potential regulatory catalysts, though the article provides no financial figures or specific catalyst timing.